Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.
Science Policy Alerts

Site Tools

  • AAAS
  • Subscribe
  • Feedback

Site Search

Search Advanced

Science 13 December 2002:
Vol. 298. no. 5601, pp. 2113 - 2115
DOI: 10.1126/science.298.5601.2113
Prev | Table of Contents | Next

News of the Week

GENE THERAPY:
RAC's Advice: Proceed With Caution

Jocelyn Kaiser

BETHESDA, MARYLAND--The cancer that appeared earlier this year in a patient who took part in a French gene therapy trial appears to have been caused by a rare combination of factors, a panel of experts concluded at a meeting here last week. The risk of a second occurrence seems sufficiently remote, the panel agreed, that this trial and others like it should go forward.

Read the Full Text


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Standards for gene therapy clinical trials based on pro-active risk assessment in a London NHS Teaching Hospital Trust.
K.B. Bamford, S. Wood, and R.J. Shaw (2005)
QJM 98, 75-86
   Abstract »    Full Text »    PDF »


ADVERTISEMENT
Click Me!

ADVERTISEMENT
Click Me!

To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)